Louise Frederika Kooij Sells 40,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 40,000 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $30.20, for a total transaction of $1,208,000.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $735,460.60. The trade was a 62.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $31.73 on Friday. The stock’s 50-day simple moving average is $32.81 and its 200 day simple moving average is $33.14. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of -17.73 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 52-week low of $17.91 and a 52-week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million during the quarter. On average, research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NAMS shares. Truist Financial started coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price on the stock. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.60.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. boosted its stake in shares of NewAmsterdam Pharma by 1.4% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock valued at $594,388,000 after purchasing an additional 241,818 shares in the last quarter. Capital World Investors raised its position in NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock worth $350,239,000 after purchasing an additional 161,289 shares during the period. Wellington Management Group LLP raised its position in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after purchasing an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Finally, Polar Capital Holdings Plc lifted its stake in NewAmsterdam Pharma by 15.6% in the third quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after purchasing an additional 393,855 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.